What is Biohaven's market cap?

Biohaven (BHVN) has a market capitalization of $2.3B and trades on NYSE.

Who are Biohaven's competitors?

Biohaven's key competitors include Xenon Pharmaceuticals Inc, Rapport Therapeutics, Inc. Common Stock, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.

Who does Biohaven partner with?

Biohaven's notable partners include Pfizer Inc..

What subsidiaries does Biohaven have?

Biohaven's subsidiaries include Biohaven Pharmaceuticals Inc..

Where is Biohaven headquartered?

Biohaven is headquartered in United States of America and employs approximately 239 people. It has been publicly traded since 2022.

Biohaven (BHVN) Stock Fundamentals & Financials

Biohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology.

Market cap

$2.33B+164%

Net income-$647.7M+27.1%

Free cash flow-$594.5M+8.4%

EPS (diluted)-$5.58+39.9%

Trailing twelve months · change vs. prior year

Earnings

Q3 2026 report

October 29, 2026

EPS-$0.86Miss by $0.08

Read the full report

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation & ratios

Valuation

See full

Market cap$2.33B+164%

Enterprise value$2.34B+37.8%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Competitors

By market cap

Eli Lilly$1.26T+63.5%

Xenon Pharmaceuticals$3.6B+12.1%

Biohaven$2.3B+28.0%

Vir Biotechnology, Inc.$1.9B+131%

ProShares UltraPro Short NASDAQ Biotechnology$1.9B+25.7%

Rapport Therapeutics, Inc.$1.4B+5.7%

PAS

Passage Bio, Inc.$11.1M-54.5%

SCN

Scienture Holdings, Inc.$5.3M-80.2%

By revenue growth

Vir Biotechnology, Inc.+1,496%

Eli Lilly+45.5%

Xenon Pharmaceuticals-100%

By net margin

Eli Lilly31.9%+0.9pp

Vir Biotechnology, Inc.-83.0%+2,813pp

Xenon Pharmaceuticals-4,612.13%—

Profile

Biohaven is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies for immunology, neuroscience, and oncology. The company leverages proprietary drug development platforms, including extracellular protein degradation, to advance a diverse pipeline of treatments for high-unmet-need conditions such as epilepsy and metabolic disorders.

Competitive position

A late-stage clinical developer focused on high-value therapeutic areas following its spin-off from its former parent company.

GeographiesGlobal

Customer segmentsHealthcare providers, Patients

Business modelR&D intensive, IP licensing, Drug development

SuppliersContract manufacturing organizations, Clinical research organizations, Academic research institutions

CustomersHospitals, Specialty pharmacies, Wholesale distributors

CountryUnited States of America

Listed2022

Employees239.0

CEOVladimir Coric

SectorHealthcare

IndustryBiotechnology

Websitebiohavenpharma.com

FilingsSEC EDGAR

FAQ

What is Biohaven's market cap?: Biohaven (BHVN) has a market capitalization of $2.3B and trades on NYSE.
Who are Biohaven's competitors?: Biohaven's key competitors include Xenon Pharmaceuticals Inc, Rapport Therapeutics, Inc. Common Stock, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
Who does Biohaven partner with?: Biohaven's notable partners include Pfizer Inc..
What subsidiaries does Biohaven have?: Biohaven's subsidiaries include Biohaven Pharmaceuticals Inc..
Where is Biohaven headquartered?: Biohaven is headquartered in United States of America and employs approximately 239 people. It has been publicly traded since 2022.